Search research articles
Contact Us
Filters
Showing results (51-60 of 59) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 59 results.
Annals of Hematology
|
April 14, 2023
Prognostic relevance of sarcopenia, geriatric, and nutritional assessments in older patients with diffuse large B-cell lymphoma: results of a multicentric prospective cohort study
Juliette Pénichoux, Hélène Lanic, Caroline Thill, et al.
Annals of Hematology
|
October 25, 2023
Correction to: Prognostic relevance of sarcopenia, geriatric, and nutritional assessments in older patients with diffuse large B‑cell lymphoma: results of a multicentric prospective cohort study
Juliette Pénichoux, Hélène Lanic, Caroline Thill, et al.
Clinical Nutrition ESPEN
|
May 18, 2023
High prevalence of pre-existing sarcopenia in critically ill patients with hematologic malignancies admitted to the intensive care unit for sepsis or septic shock
Antoine Herault, Emilie Lévêque, Simon Draye-Carbonnier, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
February 25, 2014
FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2)
Pierre Vera, Sandrine Mezzani-Saillard, Agathe Edet-Sanson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 7, 2013
Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer
Sébastien Thureau, Philippe Chaumet-Riffaud, Romain Modzelewski, et al.
The Lancet. Oncology
|
August 12, 2024
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [<sup>18</sup>F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trial
Pierre Vera, Sébastien Thureau, Florence Le Tinier, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 30, 2025
AutoPET Challenge on Fully Automated Lesion Segmentation in Oncologic PET/CT Imaging, Part 2: Domain Generalization
Jakob Dexl, Sergios Gatidis, Marcel Früh, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 4, 2017
Phase II Study of a Radiotherapy Total Dose Increase in Hypoxic Lesions Identified by <sup>18</sup>F-Misonidazole PET/CT in Patients with Non-Small Cell Lung Carcinoma (RTEP5 Study)
Pierre Vera, Sébastien Thureau, Philippe Chaumet-Riffaud, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 27, 2025
Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung Cancer
Pierre Vera, Philippe Giraud, Sébastien Hapdey, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 59) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 59 results.
Annals of Hematology
|
April 14, 2023
Prognostic relevance of sarcopenia, geriatric, and nutritional assessments in older patients with diffuse large B-cell lymphoma: results of a multicentric prospective cohort study
Juliette Pénichoux, Hélène Lanic, Caroline Thill, et al.
Annals of Hematology
|
October 25, 2023
Correction to: Prognostic relevance of sarcopenia, geriatric, and nutritional assessments in older patients with diffuse large B‑cell lymphoma: results of a multicentric prospective cohort study
Juliette Pénichoux, Hélène Lanic, Caroline Thill, et al.
Clinical Nutrition ESPEN
|
May 18, 2023
High prevalence of pre-existing sarcopenia in critically ill patients with hematologic malignancies admitted to the intensive care unit for sepsis or septic shock
Antoine Herault, Emilie Lévêque, Simon Draye-Carbonnier, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
February 25, 2014
FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2)
Pierre Vera, Sandrine Mezzani-Saillard, Agathe Edet-Sanson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 7, 2013
Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer
Sébastien Thureau, Philippe Chaumet-Riffaud, Romain Modzelewski, et al.
The Lancet. Oncology
|
August 12, 2024
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [<sup>18</sup>F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trial
Pierre Vera, Sébastien Thureau, Florence Le Tinier, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 30, 2025
AutoPET Challenge on Fully Automated Lesion Segmentation in Oncologic PET/CT Imaging, Part 2: Domain Generalization
Jakob Dexl, Sergios Gatidis, Marcel Früh, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 4, 2017
Phase II Study of a Radiotherapy Total Dose Increase in Hypoxic Lesions Identified by <sup>18</sup>F-Misonidazole PET/CT in Patients with Non-Small Cell Lung Carcinoma (RTEP5 Study)
Pierre Vera, Sébastien Thureau, Philippe Chaumet-Riffaud, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 27, 2025
Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung Cancer
Pierre Vera, Philippe Giraud, Sébastien Hapdey, et al.
Page
of 6